NAUT (nautilus.bio) Company Short-Term Debts

Brandmark of Nautilus Biotechnology (NAUT)

The success of Nautilus Biotechnology (NAUT) is based on the precision of molecule identification, yet it requires strict control over R&D costs. The current volume of short-term loans demonstrates financial dynamics where the value of 0.01 reflects this working capital status. Meanwhile, the company faces intense pressure from tech giants in the race to implement proteomics tools in laboratories.

nautilus.bio (NAUT) - Company Short-Term Debts from 07/04/2022 to 10/30/2026

Metric breakdowns and analytics for Nautilus Biotechnology, Inc. (NAUT)

- current quotes and average value forecast:
Price Chart Nautilus Biotechnology Inc|NAUT - Broker Consensus Forecast
- business market valuation indicators:
Market Capitalization Nautilus Bio|NAUT - Enterprise Value
- business book valuation details:
Accounting Value per Share Nautilus Biotechnology|NAUT - Book Capitalization|Market Cap to Net Assets Ratio nautilus.bio|NAUT - Aggregate Business Assets
- debt level and financial liquidity data:
Total Debt to Capital Nautilus Biotechnology|NAUT - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Nautilus Biotechnology Inc|NAUT - Company Debts|Debt to Book Value Nautilus Bio|NAUT - Company Long-Term Debts|Company Short-Term Debt Nautilus Biotechnology|Quick Liquidity Indicator nautilus.bio
- earnings and valuation multiples indicators:
NAUT - Final Profit
Fundamental company valuation:nautilus.bio - NAUT
Manufactured products of Nautilus Biotechnology Inc

This metric aggregates short-term loan and credit obligations, determining the current level of credit pressure on the company's liquidity prior to the next reporting update. For Nautilus Biotechnology (NAUT), which is in the pre-commercial stage of developing its proteomic platform, the dynamics of financial liabilities with maturities of up to 12 months are critical, as the absence of revenue makes the company dependent on external financing until it achieves technological superiority.

Competitors of Nautilus Biotechnology (NAUT)

TEM - Company Short-Term Debt|QGEN (Qiagen NV) - Company Short-Term Indebtedness|IONS: Company Short-Term Debts|Repligen Inc. (RGEN) - Company Short-Term Debts|Company Current Liabilities RNA|Company Short-Term Debts crisprtx.com|Company Current Liabilities WGS (GeneDx)|Amount of Current Liabilities RARE|Company Short-Term Debts BEAM (Beam Therapeutics Corp)|Short-Term Debt Volume Sarepta Corp (SRPT)|TWST - Company Short-Term Debt|TXG: Company Short-Term Debt|NTLA (Intellia Therapeutics, Inc.) - Company Current Liabilities|Stoke Therapeutics Inc (STOK) - Company Short-Term Debts|Company Short-Term Debt BioLife Corp|Wave Pharma (WVE) - Short-Term Debt Volume|Company Current Liabilities MAZE (Maze Therapeutics Inc)|SION (sionnatx.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debts PRME (Prime Medicine)|Taysha Gene Therapies Inc - Company Short-Term Debt|uniQure Corp - Company Short-Term Debts|Short-Term Debt Volume MeiraGTx Corp MGTX|REGENXBIO Inc. (RGNX) - Company Short-Term Debt|Short-Term Debt solidbio.com (SLDB)|Company Current Liabilities OCGN|PACB (Pacific Biosciences of California, Inc.) - Amount of Current Liabilities|Company Short-Term Debts BNTC|DSGN - Short-Term Debt|Company Short-Term Debts RCKT (Rocket Pharmaceuticals)|FDMT - Company Current Liabilities|Lexeo - Company Short-Term Debts|Company Short-Term Loans and Borrowings KRRO (Korro Bio, Inc.)|Editas (EDIT) - Company Short-Term Debt|Company Short-Term Indebtedness SLN|Company Short-Term Debt ProQR|Short-Term Debt Codexis Bio CDXS|Company Short-Term Debt Sangamo Therapeutics, Inc. (SGMO)|Company Short-Term Debt MGX (Metagenomi Inc.)|Company Short-Term Debt Precision BioSciences DTIL|Generation Bio Co (GBIO) - Short-Term Debt|Boundless Bio, Inc. - Company Short-Term Debts|Short-Term Indebtedness Exicure, Inc. (XCUR)|IMNN (imunon.com) - Company Current Liabilities|Short-Term Debt Phio Pharmaceuticals Corp. (PHIO)|Company Short-Term Debt Mustang Bio Inc|Company Short-Term Indebtedness RNAZ (TransCode)|Company Short-Term Debts BNGO|Company Short-Term Debts adnas.com (APDN)|bluebird bio - Company Current Liabilities|Company Short-Term Debts ImmunoPrecise Antibodies Ltd IPA|OMGA: Company Current Liabilities|Singular Genomics Corp - Amount of Current Liabilities|RGLS: Company Short-Term Debts|Company Short-Term Indebtedness SYRS|Company Short-Term Debt Telesis Bio|Company Short-Term Indebtedness TCON (TRACON Pharmaceuticals Inc.)|Company Short-Term Debts UBX